Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry
复制标题
DOI：
10.1093/annonc/mdr065
复制
发表时间：
2012-02-01
影响因子：
50.5
通讯作者：
Abrahamova, J.
中科院分区：
文献类型：
--
作者：
Buchler, T.;Klapka, R.;Abrahamova, J.
背景资料：尽管缺乏随机试验，但酪氨酸激酶抑制剂（TKI）舒尼替尼和索拉非尼序贯治疗是晚期/转移性肾细胞癌（mRCC）患者的常见治疗选择。这种回顾性登记为基础的研究的目的是分析与舒尼替尼，索拉非尼或索拉非尼，舒尼替尼sequence.Patients和方法治疗RCC患者的结果：捷克的数据库中包含的信息治疗mRCC患者使用靶向药物被用作数据源进行回顾性分析。结果：舒尼替尼-索拉非尼序贯治疗组的无进展生存期（PFS）为17.7个月，索拉非尼序贯治疗组的PFS为18.8个月（P = 0.47）。舒尼替尼-索拉非尼联合治疗患者的1年总生存率（OS）为83% [95%置信区间（CI）77%-90%]，索拉非尼-舒尼替尼联合治疗患者为84%（95% CI 77%-91%）（P = 0.99）。治疗的毒性作用是可以预测的，但一个显着比例的患者（高达14%-25%的不同线的治疗和使用TKI）之间切换TKI或停止TKI治疗，因为toxicity.Conclusions：在大多数以前发表的报告相反，我们没有观察到改善PFS或OS的mRCC患者治疗索拉非尼-舒尼替尼序列相比，舒尼替尼-索拉非尼序列。
Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib-sorafenib or sorafenib-sunitinib sequence.Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib-sorafenib sequence and 122 patients treated with sorafenib-sunitinib sequence.Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib-sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib-sorafenib and 84% (95% CI 77% to 91%) for sorafenib-sunitinib patients (P = 0.99). Treatment toxic effects were predictable but a significant proportion of patients (up to 14%-25% for different lines of therapy and used TKI) switched between TKIs or discontinued TKI therapy because of toxicity.Conclusions: In contrast to most of the previously published reports, we have not observed improved PFS or OS for mRCC patients treated with the sorafenib-sunitinib sequence as compared to the sunitinib-sorafenib sequence.